DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma

Bone Marrow Transplantation

Volumn 28, Issue 9, 2001, Pages 835-839

  Lazzarino, M ^a   Corso, A ^a   Barbarano, L ^b   Alessandrino, E P ^a   Cairoli, R ^b   Pinotti, G ^c   Ucci, G ^d   Uziel, L ^e   Rodeghiero, F ^f   Fava, S ^g   Ferrari, D ^h   Fiumano M ⁱ   Frigerio, G ^h   Isa, L ^c   Luraschi, A ^c   Montanara, S ^c   Morandi, S ^j   Perego, D ^k   Santagostino, A ^l   Savare M ^m   Vismara, A ⁿ   Morra, E ^b   more..

^a UNIVERSITY OF PAVIA   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c Division of Oncology   (Italy)

^d Division of Oncology   (Italy)

^e Division of Medical Oncology   (Italy)

^f Division of Hematology   (Italy)

^g Division of Internal Medicine 2   (Italy)

^h Division of Internal Medicine   (Italy)

ⁱ Division of Oncology   (Italy)

^j Division of Hematology   (Italy)

^k Division of Internal Medicine   (Italy)

^l Division of Oncology   (Italy)

^m Division of Internal Medicine   (Italy)

ⁿ Division of Internal Medicine 2   (Italy)

more..

Author keywords

Chemotheraphy; Mobilization; Myeloma; Peripheral stem cell; Purging in vivo

Indexed keywords

ALKYLATING AGENT; CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR;

ADULT; AGED; APHERESIS; ARTICLE; AUTOTRANSPLANTATION; BLOOD TRANSFUSION; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HOSPITALIZATION; HUMAN; HUMAN CELL; INFECTION COMPLICATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SALVAGE THERAPY; SEPSIS; THROMBOCYTOPENIA;

ADULT; AGED; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELL COUNT; BONE MARROW PURGING; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; TREATMENT OUTCOME;

EID: 0035200513     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703240     Document Type: Article

References (38)

1. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European Group for Blood and Marrow Transplantation
2. Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome
3. Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma
4. Allogeneic bone marrow transplantation in multiple myeloma: Single-center experience of 97 patients
5. Allogeneic stem cell transplantation in multiple myeloma: A report of the Société Française de Greffe de Moëlle
6. Autologous and allogeneic transplantation for multiple myeloma at a single centre
7. Allogeneic bone marrow transplantation in multiple myeloma
8. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma
9. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
10. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation
11. Quantitative analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay and the COBAS AMPLICOR CMV MONITOR PCR test after blood and marrow allogeneic transplantation
12. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia
13. Regimen-related toxicity in patients undergoing bone marrow transplantation
14. The syndrome of hepatic veno-occlusive disease after marrow transplantation
15. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients
16. Hepatic veno-occlusive disease - Liver toxicity syndrome after bone marrow transplantation
17. 1994 Consensus Conference on Acute GVHD Grading
18. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcome
19. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors
20. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: A Southwest Oncology Group study
21. Nonparametric estimation from incomplete observations
22. Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma
23. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma
24. Treatment of myeloma using intensive therapy and allogeneic bone marrow transplantation
25. Allogeneic bone marrow transplant for multiple myeloma (letter)
26. Allogeneic transplantation reduces disease progression compared to autologous transplantation for patients with myeloma
27. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia
28. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma
29. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres
30. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation
31. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: Predictive factors for response and long-term outcome
32. Graft-versus-myeloma effect: Proof of principle
33. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
34. Genes encoding tumor-specific antigens are expressed in human myeloma cells
35. Immunodominant minor histocompatibility antigens: The major ones
36. Human minor histocompatibility antigens: New concepts for marrow transplantation and adoptive immunotherapy
37. Adjuvant alpha-interferon improves complete remission rates following allogeneic transplantation for multiple myeloma
38. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma